[Integrated therapeutic strategy in large bowel neoplastic occlusion. An innovative therapeutic protocol].
BACKGROUND
Occlusive complication is a common event in the colo-rectal cancer (20-30% of cases). Operative mortality and 5 yrs survival of not occlusive cancer vs occlusive cancer is 11% vs 23% and 45% vs 25% rispectively. In occlusive cancer the level of parietal infiltration affects considerably the local and peritoneal recurrence. 50% of all patients underwent a surgical re-operation for colo-rectal cancer have peritoneal neoplastic implant.


OBJECTIVE
The resolution of occlusive complication in immediate or delayed urgency with decompressive derivation, it allows to perform an integrated treatment of choice that it could guarantee the oncological radical procedure. RATIONALE-METHODS: The intraperitoneal hyperthermic chemotherapy (IPHC) combined with radical or cytoriductive surgery performs its action through sinergistic effects of high dosage and concentration of drugs and hyperthermia. These agents perform a cell killing with a direct contact against micro and/or macroscopic neoplastic residue.


RESULTS
In radical surgery with curative intent, the association with IPHC ("preventive" adjuvant) has got as objective the distruction of microscopic local or peritoneal metastasis. In occlusive cancer with synchronous or metachronous peritoneal carcinomatosis, the performance of the cytoreductive surgery with IPHC ("therapeutic" adjuvant) is the only treatment that improves the survival and the quality of remainig life.


CONCLUSIONS
The clinical results reported by many Istitutions indicates that the 2-5 yrs survivals are 45-60% and 20-30% rispectively. These data lead us to believe that an optimal eradication of micro and/or macroscopic peritoneal spreading could be optained also in occlusive colo-rectal cancer.
Gattai
Riccardo
R
Università degli Studi di Firenze, Azienda Ospedaliera Universitaria Careggi, Centro di Riferimento Regionale di Terapie Locoregionali Perfusionali in Oncologia.
Mascitelli
Erminia Macera
EM
Bechi
Paolo
P
Pace
Marcello
M
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D003131:Combined Modality Therapy / Q000379:methods; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D007415:Intestinal Obstruction / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D007420:Intestine, Large
D000970:Antineoplastic Agents